布地奈德福莫特罗联合噻托溴铵在哮喘―慢性阻塞性肺疾病重叠综合征与慢性阻塞性肺疾病中疗效分析.docVIP

布地奈德福莫特罗联合噻托溴铵在哮喘―慢性阻塞性肺疾病重叠综合征与慢性阻塞性肺疾病中疗效分析 　　【摘要】 目的：研究比较布地奈德福莫特罗联合噻托嗅铵治疗哮喘-慢性阻塞性肺疾病重叠综合征（ACOS）与慢性阻塞性肺疾病（COPD）的临床效果，从而指导临床对ACOS的治疗。方法：选取稳定期ACOS和COPD患者各32例，观察其临床特点，以及使用布地奈德福莫特罗噻托溴铵联合治疗后用统计学分析其治疗前后肺功能及临床症状改善的情况。结果：ACOS与COPD比较，就诊年龄前者早于后者（P0.05），每年重度吸烟情况COPD患者高于ACOS患者，差异有统计学意义（P0.05），ACOS患者的基础FeNO较COPD患者有明显的升高，差异有统计学意义（P0.05）。两组患者在使用两种药物联合治疗3个月后，ACOS肺功能、临床症状的改善明显优于COPD组（P0.05）。结论：联合使用LABA/ICS和LAMA在ACOS患者中的获益高于COPD，因此临床上联合使用这两种药物治疗ACOS是有意义的。 　　【关键词】 支气管哮喘-慢性阻塞性肺疾病重叠综合征； 布地奈德福莫特罗； 噻托溴铵； 临床特征； 治疗效果 　　doi：10.14033/ki.cfmr.2018.6.002 文献标识码 A 文章编号 1674-6805（2018）06-0004-03 　　Efficacy Analysis of Budesonide Formoterol Combined with Tiotropium in Asthma-chronic Obstructive Pulmonary Disease Overlap Syndrome and Chronic Obstructive Pulmonary Disease/LIN Fang.//Chinese and Foreign Medical Research，2018，16（6）：4-6 　　【Abstract】 Objective：Comparative study on the efficacy of combination of Budesonide Formoterol and Tiotropium in the treatment of asthma-chronic obstructive pulmonary disease overlap syndrome（ACOS） and chronic obstructive pulmonary disease（COPD），and to guide the clinical treatment of ACOS.Method：Thirty-two patients with stable ACOS and COPD were divided into the experimental group and the control group.Their clinical characteristics were observed.After treatment with the combination of Budesonide Formoterol and Tiotropium，the lung function and clinical symptoms improved were analyzed according statistics.Result：ACOS compared with COPD，the age of the former was earlier than the latter（P0.05）.There was a significant difference between ACOS and COPD patients every year in heavy smoking（P0.05）.The FeNO of ACOS were significantly higher than that in COPD patients，with statistically significant difference（P0.05）.The improvement of pulmonary function and clinical symptoms of ACOS in two groups was better than that in group COPD after the combination of two drugs in 3 months（P0.05）.Conclusion：The combined use of Long-acting β2 receptor agonist/Inhaled corticosteroids a